Skip to main content
OpenTrials

Clinical trial condition

Herpes Zoster

Explore clinical trials studying Herpes Zoster. Study availability and eligibility vary by location and protocol.

175 public trials 19 recruiting studies
Refine in advanced search Browse all conditions

Herpes Zoster trial results

Completed

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster

NCT01827839

Conditions
DNA Virus Infections, Herpes Zoster, Herpesviridae Infections, +3 more
Locations
  • GSK Investigational Site Coquitlam, British Columbia, Canada
  • GSK Investigational Site Pointe-Claire, Quebec, Canada
  • GSK Investigational Site Barnaul, Russia
  • GSK Investigational Site Yekaterinburg, Russia
View Trial Details
Completed

Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older

NCT01751165

Conditions
DNA Virus Infections, Herpes Zoster, Herpesviridae Infections, +3 more
Locations
  • GSK Investigational Site Spring Valley, California, United States
  • GSK Investigational Site Wichita, Kansas, United States
  • GSK Investigational Site Uniontown, Pennsylvania, United States
  • GSK Investigational Site Tartu, Estonia
View Trial Details
Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier

NCT02581410

Conditions
DNA Virus Infections, Herpes Zoster, Herpesviridae Infections, +3 more
Locations
  • GSK Investigational Site Huntsville, Alabama, United States
  • GSK Investigational Site Daly City, California, United States
  • GSK Investigational Site Los Gatos, California, United States
  • GSK Investigational Site Oakland, California, United States
View all 32 locations
View Trial Details
Completed

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal Transplant

NCT02058589

Conditions
DNA Virus Infections, Herpes Zoster, Herpesviridae Infections, +3 more
Locations
  • GSK Investigational Site Brussels, Belgium
  • GSK Investigational Site Brussels, Belgium
  • GSK Investigational Site Ghent, Belgium
  • GSK Investigational Site Leuven, Belgium
View all 34 locations
View Trial Details
Completed

Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers

NCT01767467

Conditions
DNA Virus Infections, Herpes Zoster, Herpesviridae Infections, +3 more
Locations
  • GSK Investigational Site Inverness, Florida, United States
  • GSK Investigational Site Chicago, Illinois, United States
  • GSK Investigational Site Elkhart, Indiana, United States
  • GSK Investigational Site Boston, Massachusetts, United States
View all 86 locations
View Trial Details
Completed

A Study to Assess the Burden of Herpes Zoster and Postherpetic Neuralgia in Japanese Adults Aged Sixty Years and Above

NCT01873365

Conditions
DNA Virus Infections, Herpes Zoster, Herpesviridae Infections, +12 more
Locations
  • GSK Investigational Site Hokkaido, Japan
  • GSK Investigational Site Hokkaido, Japan
  • GSK Investigational Site Hokkaido, Japan
  • GSK Investigational Site Hokkaido, Japan
View all 14 locations
View Trial Details
Completed

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

NCT01954251

Conditions
DNA Virus Infections, Herpes Zoster, Herpesviridae Infections, +3 more
Locations
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Carnegie, Pennsylvania, United States
  • GSK Investigational Site Erie, Pennsylvania, United States
  • GSK Investigational Site Brampton, Ontario, Canada
View all 20 locations
View Trial Details

Related conditions